Table 1.
Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) Participant Characteristics (n=17)
| Characteristic | N (%) or median [IQR] |
|---|---|
| Age | 63 [58–71] |
| Male | 17 (100%) |
| Ethnicity, white | 10 (58.8%) |
| Marital status | |
| Married | 8 (47.1%) |
| Divorced/Separated/Widowed | 6 (35.4%) |
| Other | 3 (17.7%) |
| Education | |
| High school or GED | 2 (11.8%) |
| Some college | 11 (64.7%) |
| College graduate or postgraduate education | 3 (17.7%) |
| Unknown | 1 (5.9%) |
| NYHA class | |
| I | 2 (11.8%) |
| II | 8 (47.1%) |
| III | 6 (35.3%) |
| IV | 1 (5.9%) |
| Comorbidities | |
| Diabetes | 6 (35.3%) |
| Hypertension | 12 (70.6%) |
| COPD | 4 (23.5%) |
| Sleep apnea | 5 (29.4%) |
| History of depression | 3 (17.7%) |
| History of alcohol abuse | 4 (23.5%) |
| History of other substance abuse | 3 (17.7%) |
| Etiology of heart failure | |
| Ischemic | 6 (35.3%) |
| Hypertension | 3 (17.7%) |
| Alcohol induced | 2 (11.8%) |
| Unknown | 6 (35.3%) |
| Medications | |
| Beta blocker | 12 (70.6%) |
| ACE or ARB | 10 (58.8%) |
| Aldosterone antagonist | 8 (47.1%) |
| Loop diuretic | 11 (64.7%) |
| Vasodilators | 4 (23.5%) |
| Digoxin | 6 (35.3%) |
| Antidepressants | 7 (41.2%) |
| Opiates | 5 (29.4%) |
| Nonopioid analgesic | 4 (23.5%) |
| Neuropathic pain medications | 4 (25.5%) |
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; NYHA, New York Heart Association.